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ABSTRACT 
Background and Purpose 
Oral anticoagulants (OAC) substantially reduce risk of stroke in atrial fibrillation (AF), but 
uptake is suboptimal. Electronic health records (EHRs) enable automated identification of 
people at risk but not receiving treatment. We investigated the effectiveness of a software 
tool (AURAS-AF) designed to identify such individuals during routine care, through a 
cluster-randomised trial.  
Methods 
Screen reminders appeared each time the EHR of an eligible patient was accessed until a 
decision had been taken over OAC treatment. Where OAC was not started, clinicians were 
prompted to indicate a reason. Control practices continued usual care. The primary outcome 
was the proportion of eligible individuals receiving OAC at six months. Secondary outcomes 
included rates of cardiovascular events and reports of adverse effects of the software on 
clinical decision making. 
Results 
Forty-seven practices were randomised. The mean proportion prescribed OAC at 6 months 
was 66.3% (SD=9.3) in the intervention arm and 63.9% (9.5) in the control arm, adjusted 
difference: 1.21% (95% CI -0.72, 3.13). Incidence of recorded transient ischaemic attack 
(TIA) was higher in the intervention practices (median 10.0 versus 2.3 per 1000 patients with 
AF, P=0.027), but at twelve months we found a lower incidence of both all cause stroke 
(p=0.06) and haemorrhage (p=0.054). No adverse effects of the software were reported. 
Conclusions 
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No significant change in OAC prescribing occurred. A greater rate of diagnosis of TIA 
(possibly due to improved detection or over-diagnosis) was associated with a reduction (of 
borderline significance) in stroke and haemorrhage over 12 months.  
Clinical trial registration 
ISRCTN55722437.  
http://www.isrctn.com/ISRCTN55722437 
 
 
INTRODUCTION 
Atrial fibrillation (AF) is a major risk factor for thromboembolic stroke.[1] Oral 
anticoagulants (OACs) reduce stroke risk in AF by 60-70%[2-3] but their uptake is 
suboptimal.[4-5] Risk factors for stroke are generally well recorded in UK primary care 
electronic health records (EHRs), providing an opportunity for automated risk assessment. 
We developed a software tool, AURAS-AF within a web-based EHR system and conducted a 
cluster-randomised trial to measure its impact and confirm its safety.[6] 
METHODS 
This was a cluster-randomised trial across practices in South East and Central England. 
Intervention 
The AURAS-AF tool drew on the data in the records of patients with AF, and identified those 
fulfilling the eligibility criteria for OAC at that time.[7] 
It functioned in two ways: 
1. At the start of the trial, practices were asked to invite a list of eligible patients for a 
discussion over anticoagulants.  
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2. If a patient identified as eligible for but not using OAC was seen at the practice by a 
clinician, a screen reminder message would appear. 
The tool was designed to challenge clinicians to justify treatment decisions at the point of 
care, when the patient would be present. There was no requirement imposed by the trial to 
adhere to guidelines or follow any specific treatment pathway. 
Control practices 
Practices allocated to the control arm continued to provide usual care to AF patients, 
including the requirements of the Quality and Outcomes Framework (QOF) funding 
system.[8] 
Outcome measures 
Primary outcome  
The primary outcome was the proportion of patients eligible for OAC who were currently 
prescribed an OAC at the end of the 6 months intervention period.  
Secondary outcomes 
1) Proportion with CHADS2 score ≥2 currently prescribed OAC at 6 months; 2) Practices 
were asked to report instances of inappropriate clinical or prescribing decisions related to 
anticoagulation in patients with AF; Incidences of: 3) Thromboembolic stroke, TIA, or 
systemic (arterial) thromboembolism; 4) Haemorrhagic stroke and other haemorrhagic 
events; Incidence rates for the following events were added on the advice of the Data 
Monitoring Committee: 5) Thromboembolic stroke; 6) TIA; 7) Systemic thromboembolism; 
8) Haemorrhagic stroke; 9) Other haemorrhagic events; 10) Unspecified stroke events; 11) 
All cause stroke (thromboembolic, haemorrhagic or unspecified).   
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All outcomes were measured at 6 months and repeated at 12 months (6 months following the 
end of the intervention period). 
Audit of cardiovascular events 
Each thromboembolic or haemorrhagic event occurring during the intervention period was 
investigated to identify whether it might have resulted from use of the software, for instance 
through inappropriate prescribing decisions.  
Allocation 
Practices were randomised with an allocation ratio of 1:1, minimised on practice list size and 
proportion of eligible patients with AF prescribed OACs at baseline. 
Data collection 
Anonymised outcome data from the practices were extracted via a virtual private network 
(VPN) linked to Oxford University. This source includes all electronically coded information, 
including diagnoses and medication.   
Sample size 
We estimated that a sample of 46 practices would be needed for 95% power to detect a 
relative difference of 25% in the primary outcome with 5% significance.[6]  
Statistical analysis 
Statistical analyses were undertaken using SPSS version 22 and Stata 13 on an intention to 
treat basis. Cluster summary measures were analysed using a weighted linear regression 
model with the minimisation variables fitted as covariates. If assumptions of linear regression 
were violated, a Mann-Whitney U test was applied.   
RESULTS 
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We approached 570 potentially eligible practices, 70 expressed interest, and 47 were 
randomised (Figure). One withdrew during the first three months of the trial, leaving 46 in 
the intention to treat sample. These provided a combined patient population of 359,937 with 
6,429 patients with AF at baseline (20th February 2014), of which 5,339 (83%) were eligible 
for OAC and of these, 3,340 (62.6%) were already treated. The population characteristics 
were similar in each arm (Table).  
Primary outcome 
The mean proportion (SD) of eligible patients prescribed OAC at six months was 66.3% 
(9.25) in the intervention arm and 63.9% (9.46) in the control arm. The adjusted mean 
difference (95% CI) was 1.21% (-0.72, 3.13), P=0.213.  
Secondary outcomes 
The proportion in the subgroup with a CHADS2 score ≥2 prescribed anticoagulants at the end 
of the study was not significantly different between trial arms. There were no reports of 
inappropriate clinical or prescribing decisions or cardiovascular events triggered by use of the 
software. Practice based searches supporting the cardiovascular event audit confirmed the 
validity of the remote data extraction. 
The Table gives the incidence of cardiovascular events during the 6 and 12 month time 
periods following randomisation. The increased rate of thromboembolic events in the 
intervention arm is due to a higher rate of TIA diagnosis with no increase in thromboembolic 
stroke or unspecified stroke. In fact there is a reduction of borderline significance in strokes 
of all types (P=0.06) and of haemorrhage (p=0.054) at 12 months. 
DISCUSSION 
Strengths and limitations 
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This was a pragmatic randomised trial involving a diverse range of practices across a wide 
geographical area using a modern, web-based EHR platform.  
Comparison to other studies  
The findings concur with other studies demonstrating small or modest impacts of reminder 
interventions on clinician behaviour.[9]  
Interpretation 
Since the trial was conceived there has been a refocussing of the identification problem away 
from those eligible for OAC and towards the minority who do not require it,[10] making 
stroke risk assessment less important compared with other more difficult barriers. Decisions 
over anticoagulation may take longer to make than our six month intervention period. A 
longer follow up might also be required to confirm the improvements in stroke and 
haemorrhage rates suggested by our data.  
CONCLUSIONS 
Use of the software was associated with no significant change in prescribing, but improved 
stroke and haemorrhage rates (of borderline significance) at 12 months.  
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Table: Baseline characteristics and incidence of cardiovascular events in AF patients 
over 6 and 12 months  
 Control Intervention  
Baseline characteristics Median (IQR) unless indicated  
List size 7039 (4724, 
10832) 
6803 (4071, 
11368) 
 
Prevalence of AF per 100 patients 1.71 (1.11, 2.20) 1.92 (1.77, 2.21)  
Proportion of AF patients who are female 44.6% (40.9, 
50.0) 
46.3% (42.4, 
50.0) 
 
Proportion of AF patients under 80 years 56.5% (51.0, 
62.3) 
56.9% (51.6, 
59.8) 
 
Proportion eligible for OAC and 
prescribed OAC at baseline1 
61.9% (9.89) 63.5% (8.85)  
Events Incidence (patients with at least one 
event per 1000 AF patients) 
P Value2 
 
Thromboembolic stroke, 
TIA or other major 
thromboembolism 
 N=23 N=23  
6 months 0 (0, 7.75) 10.3 (0, 16.3) 0.03 
12 months 12.6 (0, 22.3) 14.5 (4.2, 26.1) 0.41 
Haemorrhage (including 
haemorrhagic stroke)3 
6 months 26.5 (15.0)1 21.0 (14.7)1 0.414 
 
12 months 50.3 (33.4, 57.3) 34.7 (27.4, 43.6) 0.054 
All cause stroke3 6 months 8.5 (0, 17.7) 7.9 (0, 13.4) 0.43 
12 months 24.8 (19.3, 28.9) 15 (9.1, 28.3) 0.06 
Transient ischaemic attack 6 months 0 (0,0) 6.4 (0, 12.2) 0.008 
12 months 2.3 (0, 9.0) 10.0 (4.2, 18.2) 0.027 
Thromboembolic stroke 6 months 0 (0, 0) 0 (0, 4.1) 0.40 
12 months 0 (0, 12.8) 0 (0, 5.0) 0.36 
Haemorrhagic stroke3 6 months 0 (0,0)1 0 (0,0)1 0.82 
12 months 0 (0, 0.96) 0 (0, 3.14) 0.92 
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Unspecified stroke 6 months 5.2 (0, 16.4) 3.2 (0, 9.4) 0.26 
12 months 17.0 (11.4)1 13.3 (11.0)1 0.394 
1 Mean (SD)  
2 Mann Whitney U test 
3 N=22 in the control arm for haemorrhagic event searches (see Figure). The other searches were unaffected. 
4 P value obtained from weighted linear regression. 
 
 
FIGURE LEGEND 
Flow diagram of trial participants 
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